BeOne Medicines showcases sustained leukemia control with long-term Brukinsa data
BeOne Medicines (NASDAQ:ONC) is moving to advance the treatment paradigm for chronic lymphocytic leukemia (CLL) with extensive long-term follow-up data slated for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.










